Secondary Causes of Bone Fragility in Postmenopausal Women
In a postmenopausal woman with a fragility fracture, you must systematically evaluate for secondary causes of osteoporosis, which are present in 50-67% of such patients and fundamentally alter treatment approach. 1, 2
Why This Matters
Secondary causes are found in approximately 50% of postmenopausal women with osteoporosis and 67% of those with low bone mineral density who present with fragility fractures 1. Critically, these secondary factors occur equally across all BMD categories—including those with normal BMD, osteopenia, and osteoporosis 2. This means you cannot rely on BMD alone to determine who needs evaluation.
Specific Conditions to Evaluate
Endocrine Disorders
- Hypercortisolism (including mild autonomous cortisol secretion—MACS—which causes fractures even at near-normal cortisol levels) 3
- Primary hyperparathyroidism (preferentially decreases cortical bone at hip and radius) 4
- Secondary hyperparathyroidism (found in 6% of fracture patients) 2
- Hyperthyroidism (untreated, long-standing) 5
- Hypogonadism or premature menopause 5
- Primary aldosteronism (promotes fragility via mineralocorticoid receptor activation, oxidative stress, and hypercalciuria) 3
Metabolic and Nutritional Disorders
- Vitamin D deficiency (when severe, causes osteomalacia with bone pain and muscle weakness, not just asymptomatic osteoporosis) 6
- Hypercalciuria (PTH-dependent vs. PTH-independent—differentiation is crucial for management) 3
- FGF23-dependent phosphate-wasting disorders (impair mineralization) 3
- Chronic malnutrition or malabsorption 5
- Chronic liver disease 5
Hematologic Conditions
- Monoclonal gammopathy (found in 13% of fracture patients) 2
Renal Disease
- Chronic kidney disease (present in 13% of fracture patients) 2
Rheumatologic Conditions
- Rheumatoid arthritis (accounts for 3% of cases, included in FRAX) 4, 2
- Ankylosing spondylitis 7
- Systemic lupus erythematosus 7
- Other erosive inflammatory arthritides 7
Medication-Induced Bone Loss
- Glucocorticoids (≥5 mg prednisone daily for ≥3 months—found in 12% of fracture patients) 8, 2
- Anti-androgenic therapy for prostate cancer 7
- Aromatase inhibitor therapy for breast cancer 7
Lifestyle and Behavioral Factors
- Chronic alcoholism (>3 drinks daily—found in 12% of fracture patients) 5, 2
- Current smoking (18% of fracture patients) 2
- Type 1 diabetes 5
- Osteogenesis imperfecta in adults 5
Structured Laboratory Evaluation
For any postmenopausal woman with a fragility fracture, obtain these specific tests (92% sensitivity for detecting secondary causes) 6:
Essential Laboratory Panel
- 25-hydroxyvitamin D (not 1,25-dihydroxyvitamin D)
- Parathyroid hormone (PTH)
- Serum calcium and phosphate
- 24-hour urine calcium
- Serum creatinine (assess renal function)
- Complete blood count (screen for hematologic disorders)
- Liver function tests
- Thyroid-stimulating hormone
- Serum protein electrophoresis (given 13% prevalence of monoclonal gammopathy) 2
Additional Tests Based on Clinical Suspicion
- Testosterone in men with hypogonadism
- 24-hour urinary free cortisol or overnight dexamethasone suppression test if Cushing's suspected
- Tissue transglutaminase antibodies if malabsorption suspected
Critical Clinical Pitfalls
Don't assume normal BMD excludes secondary causes: 17% of patients with normal BMD have secondary factors contributing to their fracture 2
Don't skip evaluation in "typical" osteoporosis: Even postmenopausal women who appear to have primary osteoporosis have a 50% chance of having a treatable secondary cause 1
Recognize vitamin D deficiency vs. osteomalacia: Severe vitamin D deficiency presents with bone pain, muscle weakness, low calcium/phosphorus, elevated alkaline phosphatase and PTH—not just low BMD 6
HIV infection is a risk factor: All HIV-infected postmenopausal women should be screened, as HIV itself is associated with low BMD independent of other factors 6
When to Suspect Secondary Osteoporosis
Evaluate for secondary causes in these specific scenarios 5:
- Any fragility fracture regardless of BMD
- Z-score ≤ -2.0 (suggests secondary cause rather than age-related bone loss) 4
- Premenopausal women with low BMD or fracture
- Men of any age with low BMD or fracture
- Postmenopausal women <65 years with fracture
- Rapid bone loss on serial DXA (>3-5% annually at spine or hip)
- Fracture despite adequate osteoporosis treatment
Why This Changes Management
Identifying secondary causes is not academic—many are reversible or require specific treatment beyond standard osteoporosis therapy 7, 9. For example:
- Correcting vitamin D deficiency prevents osteomalacia
- Treating hyperparathyroidism may reverse bone loss
- Discontinuing causative medications when possible
- Addressing hypercortisolism improves bone quality
- Treating malabsorption restores calcium absorption
The presence of secondary osteoporosis increases fracture risk 2-3 fold beyond what BMD alone would predict 6, making identification and treatment essential for effective fracture prevention.